{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastasis%2C+Neoplasm&page=34", "query": { "condition": "Metastasis, Neoplasm", "page": 34 }, "page_size": 10 }, "pagination": { "page": 34, "page_size": 10, "total_count": 10744, "total_pages": 1075, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastasis%2C+Neoplasm&page=35&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastasis%2C+Neoplasm&page=33&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T07:33:57.705Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02027961", "title": "Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2013-12-20", "completion_date": "2018-04-24", "has_results": false, "last_update_posted_date": "2019-05-17", "last_synced_at": "2026-10-25T07:33:57.705Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02027961" }, { "nct_id": "NCT04132505", "title": "Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma", "Stage IV Pancreatic Cancer AJCC v8" ], "interventions": [ { "name": "Binimetinib", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2019-10-22", "completion_date": "2026-03-24", "has_results": false, "last_update_posted_date": "2026-04-06", "last_synced_at": "2026-10-25T07:33:57.705Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04132505" }, { "nct_id": "NCT07856394", "title": "Adding Spatially Fractionated Radiation Therapy to Standard Palliative Radiation for Improving Disease-Related Symptoms in Patients With Unresectable Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Metastatic Malignant Solid Neoplasm", "Unresectable Malignant Solid Neoplasm", "Unresectable Solid Tumor", "Malignant Tumor", "Metastatic Solid Tumor" ], "interventions": [ { "name": "Electronic Health Record Review", "type": "OTHER" }, { "name": "External Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Spatially-fractionated Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "OTHER", "RADIATION" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 100, "start_date": "2026-09-23", "completion_date": "2031-09-30", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-25T07:33:57.705Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07856394" }, { "nct_id": "NCT00574366", "title": "Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "erlotinib", "type": "DRUG" }, { "name": "RAD001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2005-12", "completion_date": "2009-02", "has_results": false, "last_update_posted_date": "2016-05-10", "last_synced_at": "2026-10-25T07:33:57.705Z", "location_count": 3, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00574366" }, { "nct_id": "NCT02448537", "title": "A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Sarcoma" ], "interventions": [ { "name": "PM01183", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 42, "start_date": "2015-08", "completion_date": "2019-04-01", "has_results": true, "last_update_posted_date": "2021-03-03", "last_synced_at": "2026-10-25T07:33:57.705Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02448537" }, { "nct_id": "NCT07063745", "title": "A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Metastatic Non-small Cell Lung Cancer With MTAP Deletion" ], "interventions": [ { "name": "BMS-986504", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 590, "start_date": "2026-01-02", "completion_date": "2031-08-12", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-25T07:33:57.705Z", "location_count": 44, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 38 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Los Alamitos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07063745" }, { "nct_id": "NCT01847495", "title": "Evaluation of Low-dose Irinotecan and Cyberknife® SBRT to Treat Colorectal Cancer With Limited Liver Metastasis", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Irinotecan", "type": "DRUG" }, { "name": "CyberKnife", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2013-10", "completion_date": "2017-11-29", "has_results": false, "last_update_posted_date": "2024-10-04", "last_synced_at": "2026-10-25T07:33:57.705Z", "location_count": 1, "location_summary": "Park Ridge, Illinois", "locations": [ { "city": "Park Ridge", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01847495" }, { "nct_id": "NCT00077883", "title": "TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "TLK286, cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Telik", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2004-02", "completion_date": "2007-03", "has_results": false, "last_update_posted_date": "2011-07-25", "last_synced_at": "2026-10-25T07:33:57.705Z", "location_count": 3, "location_summary": "Baltimore, Maryland • Nashville, Tennessee • Houston, Texas", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00077883" }, { "nct_id": "NCT06502483", "title": "PRISM for Depression and Anxiety in Young Adults With Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer Diagnosis", "Non-Metastatic Neoplasm", "Anxiety", "Anxiety Disorders", "Depression", "Depressive Disorder", "Depression, Anxiety", "Desmoid" ], "interventions": [ { "name": "Promoting Resilience in Stress Management Program", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "18 Years to 39 Years" }, "enrollment_count": 13, "start_date": "2024-09-06", "completion_date": "2026-02-01", "has_results": false, "last_update_posted_date": "2026-04-21", "last_synced_at": "2026-10-25T07:33:57.705Z", "location_count": 1, "location_summary": "Brighton, Massachusetts", "locations": [ { "city": "Brighton", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06502483" }, { "nct_id": "NCT03590054", "title": "Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Stage III Cutaneous Melanoma", "Stage IV Cutaneous Melanoma", "Locally Advanced Melanoma", "Locally Advanced Solid Neoplasm", "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Urothelial Carcinoma", "Non-Small Cell Lung Carcinoma", "Stage IB Lung Cancer AJCC v7", "Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Ureter Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Ureter Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Abexinostat", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Rahul Aggarwal", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2018-08-20", "completion_date": "2023-11-30", "has_results": false, "last_update_posted_date": "2024-03-22", "last_synced_at": "2026-10-25T07:33:57.705Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03590054" } ] }